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ABSTRACT
Gene expression technology has become a
routine application in many laboratories and has
provided large amounts of gene expression signa-
tures that have been identified in a variety of cancer
types. Interpretation of gene expression signatures
would profit from the availability of a procedure
capable of assigning differentially regulated genes
or entire gene signatures to defined cancer signal-
ing pathways. Here we describe a graph-based
approach that identifies cancer signaling pathways
from published gene expression signatures.
Published gene expression signatures are collected
in a database (PubLiME: Published Lists of
Microarray Experiments) enabled for cross-platform
gene annotation. Significant co-occurrence mod-
ules composed of up to 10 genes in different gene
expression signatures are identified. Significantly
co-occurring genes are linked by an edge in an
undirected graph. Edge-betweenness and k-clique
clustering combined with graph modularity as a
quality measure are used to identify communities
in the resulting graph. The identified communities
consist of cell cycle, apoptosis, phosphorylation
cascade, extra cellular matrix, interferon and
immune response regulators as well as commu-
nities of unknown function. The genes constituting
different communities are characterized by
common genomic features and strongly enriched
cis-regulatory modules in their upstream regulatory
regions that are consistent with pathway assign-
ment of those genes.
INTRODUCTION
Gene expression microarrays have been applied to study-
ing a wide variety of biological conditions, including
cancer. Analysis of microarray data is generally per-
formed by applying a number of ﬁltering steps, the
application of statistical tests, cluster analysis, deﬁnition
of classiﬁer gene sets, annotation of genes identiﬁed in
clusters and the validation of diﬀerential expression using
alternative techniques such as quantitative PCR. With the
accumulation of publicly accessible datasets stored in
repositories like ArrayExpress (1), GEO (2), CIBEX (3)
and Oncomine (4), it is becoming increasingly feasible to
cross-compare in-house generated data to published
datasets and to perform meta-analysis, which can be
very informative.
However, since gene expression studies are being
performed using a variety of commercially available as
well as custom microarray platforms, meta-analysis is
hampered by the need for cross-platform annotation.
As a consequence, researchers are forced to compare
their data to published data that have been generated
on compatible microarray platforms or to undergo a
painstaking cross-platform annotation eﬀort which limits
the number of datasets available for meta-analysis.
Furthermore, the diﬃculties in rendering datasets compat-
ible for meta-analysis often conditions the choice of
published datasets to those which are most ‘interesting’
from the point of view of biological intuition, precluding
the discovery of unexpected connections between diverse
datasets.
We (5) and others (6) have proposed possible solutions
to this problem by developing repositories that are helpful
in performing meta-analysis tasks and in identifying
similar datasets in an unbiased manner. Nevertheless,
despite of the use of sophisticated gene annotation tools
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interpretation of gene expression signatures remains
essentially restricted to the interpretation of gene lists
identiﬁed in isolated experiments and subject to personal
judgment, as diﬀerent hypotheses can have similar
statistical validity. Furthermore, using approaches based
on pre-assembled gene lists, discovery of unknown path-
ways is impossible.
Here we discuss a graph-based integrative approach
that identiﬁes biologically meaningful pathways from the
analysis of co-occurrence patterns observed in published
gene expression signatures. Genes whose expression is
governed by similar signals are expected to co-occur
signiﬁcantly in distinct signatures and to form a strongly
interconnected community with diﬀerent communities
being targeted by diﬀerent signaling pathways. Using
this approach, individual genes as well as entire signatures
can be assigned to pathways whose composition is entirely
determined by the signatures in the repository as well as
the signature being analyzed rather than by pre-conﬁgured
gene sets that have been grouped according to various
measures of similarity.
The analysis consists in the following steps:
(1) Identiﬁcation of signiﬁcantly co-occurring gene mod-
ules composed of up to 10 genes in the PubLiME
repository.
(2) Generation of a graph representation of co-occurring
gene modules where genes are represented by nodes
that are linked by an edge when the genes are part of
the same signiﬁcant co-occurrence module.
(3) Identiﬁcation of strongly interconnected communities
(i.e. pathways) in the resulting graph using two
diﬀerent approaches: edge-betweenness clustering
combined with graph modularity as a quality
measure (10), which identiﬁes separate communities
and k-clique clustering (11) identifying partially
overlapping communities, both yielding highly con-
sistent results.
Following this procedure, we identiﬁed communities that
correspond to deﬁned biological pathways composed of
regulators of the cell cycle, phosphorylation cascades,
apoptosis, extracellular matrix, immune and interferon
responses, as well as communities of unknown function.
We show that the genes that constitute diﬀerent commu-
nities are characterized by common genomic features
and display strongly enriched cis-regulatory modules in
their putative promoter regions that are consistent with
pathway assignment.
MATERIALS AND METHODS
Generationof arepository ofpublished
cancer genesignatures
We searched the Aﬀymetrix database of publications
using Aﬀymetrix technology and PubMed to identify
cancer-related gene expression microarray studies appear-
ing in the years 1999–2005. Four hundred ninety nine
published cancer-related gene expression microarray
studies were scrutinized for scope of the study, microarray
platforms employed, organism studied and feasibility of
cross-platform annotation of published gene expression
signatures. Two hundred seventy three studies (233 human
and 40 mouse) were selected for manual extraction of gene
expression signatures. The selected publications report
two basic types of signatures: signatures resulting
form unbiased screening of cancer specimens as well as
studies identifying diﬀerentially regulated genes in cell-
line-based model systems. Cross-platform annotation
of gene expression signatures was performed
according to a procedure described in (12). Medline
annotations of these publications were downloaded by
calling NCBI Entrez Utilities (http://utils.ncbi.nlm.nih.
gov/entrez/query/static/eutils_help.html from a Perl script
via the LWP module. Parsing of downloaded XML ﬁles
was performed by a Perl script using the DOM module.
Data regarding publications and gene expression signa-
tures were imported into a relational MySQL database
that is accessible via a web-interface (http://bio.ifom-ieo-
campus.it/publime/).
Significance of co-occurrenceof genesin gene
expression signatures
Estimates of signiﬁcance of co-occurrence of genes in a
gene expression signature are based on randomization of
signatures. Gene expression signatures are composed of
non-redundant sets of genes. Thus, randomized signatures
must be composed of non-redundant gene sets as well,
leading to constraints on the composition of randomized
signatures which precludes calculating the probability of a
gene for being part of a given signature based on the
number of signatures that a gene is part of and the number
and sizes of analyzed signatures. Therefore, a gene-swap
procedure is used where prior to swapping two genes
between signatures, a test is performed ensuring that the
genes to be swapped between signatures are not already
present in the respective target signatures. To ensure
complete randomization of signatures, the number of
swaps performed in a single simulation is chosen to be 10
times the sum of all signature sizes. Ten thousand
simulations are run and at each simulation, the pre-
sence/absence of each gene in each signature is deter-
mined. The occurrence probability of a gene in a given
signature is then calculated as the number of times the
gene was found being part of that signature divided by
10000.
Given the occurrence probabilities of genes per signature,
co-occurrence probabilities are calculated by multiplying
the occurrence probabilities of the genes under study (this
set of genes is called a module) in each signature. Co-
occurrences of two up to ten genes were analyzed.
Co-occurrence probabilities are signature-speciﬁc.
Given the co-occurrence probabilities of a module, the
signiﬁcance of the number of observed co-occurrences
must be evaluated. If co-occurrence probabilities were
equal for all signatures (which would be the case if all
signatures were of equal size), the probability distribution
of co-occurrences of a module would be given by the
Binomial Distribution in which the number of trials is
equal to the number of signatures, the number of successes
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success is the co-occurrence probability of a module.
However, the signature-speciﬁc nature of co-occurrence
probabilities caused by diﬀerences in signature sizes
implies that the co-occurrence probability distribution of
a module is given by a Binomial Distribution with trial-
speciﬁc probabilities. Calculating this distribution for
large numbers of signatures is not feasible because it
implies summation of a number of terms that is given
by the binomial coeﬃcient ðS
kÞ where k is the number
of co-occurrences and S is the number of signatures
which assumes large values even for relatively small
numbers of signatures. Therefore, we apply a Z-score
transformation to the number of co-occurrences k of a
module given by
k    
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which are the mean and standard deviation of the
Binomial Distribution, respectively.
Edge-betweenness clustering andgraph modularity
Edge-betweenness is deﬁned as the fraction of shortest
paths in a graph that pass through an edge. Edges that are
connecting two strongly interconnected communities
(hence are in between those communities) will be part of
shortest paths more often than edges within the commu-
nities when shortest paths are calculated for all nodes of
the two communities. Having identiﬁed the edge with the
largest edge-betweenness, the edge is removed from the
graph. Then, the algorithm restarts calculating shortest
paths in the remaining graph, identiﬁes the next edge with
highest edge-betweenness, removes it from the graph and
so on. The procedure is supplemented with a quality
measure (graph modularity) which tells the algorithm the
optimal number of edges to be removed from the graph.
Graph modularity is calculated as the diﬀerence of the
fraction of observed edges within a community minus the
expected fraction of edges within a community if the edges
were linking the nodes of the graph at random. This
diﬀerence is calculated for all communities and the sum
thereof represents graph modularity whose value for
highly modular graphs is found to be larger than 0.3
and rarely exceeds 0.7 (10).
Promoter analysis
The identiﬁcation of co-occurrence modules of genes is
performed using a list representation of signatures as
PubmedID-gene pairs. The identiﬁcation of cis-regulatory
modules is performed using the same software and
statistics with the only diﬀerence that lists of promoter-
motif pairs are used. To obtain these lists (supplementary
ﬁle ‘Symbol_TF.txt’), we assembled a collection of
consensus transcription regulatory motifs derived from
Transfac database (13) (supplementary table ‘consensus_
motifs.xls’). Next, we identiﬁed all matches of consensus
motifs within 500bp upstream of the annotated transcrip-
tion start site for all Refseq genes in the human genome
(UCSC hg18), excluding duplicated promoter sequences
and Refseqs with ambiguous genome mapping. Multiple
occurrences of a motif in the same promoter were ignored.
The swapping procedure described earlier was used to
obtain genome-wide occurrence probabilities for each
motif in each promoter region. Co-occurrence of combi-
nations of motifs in the promoters of community forming
genes is then analyzed and gives the number of promoters
containing the module. Modules are required to be present
in at least one-third of all promoters of community
forming genes. The promoter-speciﬁc co-occurrence prob-
ability of a module is then calculated by multiplying
the occurrence probabilities of the composing motifs.
A Z-score using the Binomial Distribution with trial-
speciﬁc probabilities is calculated as described earlier.
A Z-score cutoﬀ of 5 is chosen to deﬁne signiﬁcant cis-
regulatory modules. The same procedure is carried out in
randomized versions of promoter-motif lists for each
community. The number of signiﬁcant cis-regulatory
modules for each community and module size is divided
by the corresponding number of modules identiﬁed
in randomized promoter-motif lists so as to obtain a
signal-to-noise ratio (SNR).
In order to visualize the modules identiﬁed at the module
size giving the best signal-to-noise ratio, we generated a
graph representation of motif modules where motifs are
nodes linked by an edge if they are part of the same
signiﬁcant cis-regulatory module. In this representation,
the motif that is most frequently co-occurring with other
motifs will be characterized by a high node degree that can
be visualized by varying node size. A similar representation
is obtained using the PageRank algorithm (JUNG soft-
ware package) that, in addition to node degree, also takes
into consideration the structure of the graph in order to
identify the node that will be visited most frequently upon
random walks along the edges of a graph.
Software
Custom Java-based software was used for determining
occurrence probabilities, co-occurrence probabilities and
the identiﬁcation of signiﬁcant co-occurrence modules
from PubLiME data. JUNG (http://jung.sourceforge.net/
index.html) and Netsight (http://jung.sourceforge.net/
netsight/) software were used for edge-betweenness
clustering and graph visualization. For calculating graph
modularity, a customized Java class implementing graph
modularity calculation as described by (10) was written
and run within the JUNG framework. CFinder software
was used for k-clique clustering (11). Boxplots and Q–Q
plots were prepared using R.
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PubLiMEcontent and meta-analysis
Gene expression microarray data generated from numer-
ous studies are generally published as supplementary data
and/or they are deposited in public gene expression data
repositories like ArrayExpress (1) and GEO (2). The fact
that there are a considerable number of diﬀerent micro-
array platforms available turns meta-analysis of gene
expression data into a nontrivial task because individual
genes are often represented in a many-to-many relation-
ship on diﬀerent array platforms. While individual
experiments can be scrutinized in great depth, meta-
analysis of microarray data is concerned with cross-
experiment and often cross-platform comparison of gene
expression data (Figure 1A). Complications in this process
arise from the use of diﬀerent identiﬁers and formats in
diﬀerent publications as well as from diﬀerences in gene
content and probes employed by diﬀerent microarray
platforms.
In order to facilitate meta-analysis, we chose to generate
a repository of gene expression signatures that hosts the
diﬀerentially regulated gene sets identiﬁed by individual
studies as gene lists in a relational database (Figure 1B).
The database is composed of three logical units regarding
individual genes, gene lists (i.e. signatures) and publica-
tions. Currently, the database hosts 1041 human gene lists
collected from 233 publications and 241 mouse gene lists
from 40 publications. The types of identiﬁers used in
diﬀerent gene lists are shown in Figure 1C. Genbank
accession number is the most widely used, followed by
Aﬀymetrix probeset, gene symbol, Unigene title and
Unigene cluster identiﬁer. All identiﬁers used in publica-
tions were mapped to Entrez Gene identiﬁers. 31243
reported identiﬁers of human genes were mapped to 7476
Gene identiﬁers and 8323 reported mouse identiﬁers were
mapped to 4277 mouse Gene identiﬁers meaning that
roughly one-third of all human and mouse genes have
been reported as diﬀerentially regulated at least once.
The publications cover a wide range of diﬀerent
conditions. Figure 1D shows a classiﬁcation of publica-
tions by experimental approach. There are roughly equal
numbers of studies employing model systems and patient
samples. Some studies use both approaches. The model
systems comprise screening of cell lines with inducible
gene expression, drug/hormone/cytokine/radiation/serum/
knockdown treatment of cell lines, co-culture/infection of
cell lines with pathogens, somatic gene knockout in cell
lines and comparison of cell lines with diﬀerent tumori-
genic or drug-resistance properties. Patient samples and
model systems are derived from cancers of a wide range of
organs (Figure 1E). Publications studying cancer of blood
cells are most abundant but very heterogeneous. There are
patient sample studies on leukemia (T-ALL, B-ALL,
AML, CLL and CML), lymphoma, thymoma and many
model system studies. A complete account of conditions is
found in the supplementary ﬁle ‘conditions_overlaps.xls’.
We analyzed the occurrence frequency of genes in
published signatures and found it to be strongly uneven,
with few genes being present in more than 20 signatures
while most genes are found in less than 5 signatures
(Figure 2A). The 20 most frequently occurring genes are
listed in Table 1. Possible explanations for this distribu-
tion are biased selection of conditions, higher expression
levels of most represented genes leading to more reliable
detection and use of alternative promoters in diﬀerent
conditions, causing changing expression in a larger
number of conditions. Biased selection of conditions
appears unlikely considering the data shown in
Figure 1E, although it cannot be excluded entirely.
To test the remaining two hypotheses, we analyzed the
Unigene Hs.198 EST expression proﬁles. Expression levels
are expressed in transcripts per million in 49 diﬀerent
tissues. We tested whether the 500 most frequently
occurring genes have a signiﬁcantly higher expression
level in diﬀerent tissues than the average of all genes with
an Entrez GeneID. Wilcoxon signed rank sum tests were
performed for all tissues. The negative decadic logarithm
of the obtained P-values shown in Figure 2B illustrates
that the 500 most frequently occurring genes are indeed
expressed at higher levels in nearly all tissues. Similarly,
we analyzed whether those genes are expressed in more
tissues. A gene was considered expressed when at least one
EST corresponding to that gene has been identiﬁed in that
tissue. The last column of Figure 2B shows that the 500
most frequently occurring PubLiME genes are expressed
in a larger number of diﬀerent tissues with a highly
signiﬁcant P-value. We sought to identify common
genomic features of the 500 most frequent genes. CpG
islands covering transcription start sites are known to be
associated with promoter activity and are characterized by
frequent alternative start sites (14,15). Therefore, we
analyzed CpG island lengths of CpG islands covering
annotated transcription start sites for the 500 most cited
PubLiME genes and compared it to the genomic average.
We found that the 500 most frequently occurring genes
have signiﬁcantly longer CpG island promoters as well as
more annotated alternative 50-ends (Figure 2C), suggest-
ing that these genes might be expressed from a number of
alternative promoters responding to diﬀerent stimuli.
Apart from oﬀering an explanation for the nonuniform
distribution of gene occurrences in PubLiME, these results
suggest that PubLiME hosts biologically relevant
information.
PubLiME can be queried via a web-interface. Possible
searches include single gene searches returning all
publications where the gene has been reported as
diﬀerentially regulated, gene list searches returning pub-
lications reporting similar gene sets where similarity is
evaluated based on the hypergeometric distribution, as
well as searches regarding publications where ﬁelds such
as Authors, Abstract, Title, Mesh terms and PubMed
identiﬁers can be interrogated (Supplementary Figures S1
and S2).
Identification ofsignificant co-occurrence modules ofgenes
We interrogated PubLiME with the aim of identifying
signiﬁcantly co-occurring gene sets composed of up to
10 genes. We call a set of signiﬁcantly co-occurring genes a
co-occurrence module and the number of co-occurring
genes the module size (Figure 3A). This nomenclature was
2346 Nucleic Acids Research, 2007, Vol. 35, No. 7Figure 1. PubLiME, a repository of published gene expression signatures. (A) PubLiME stores gene expression signatures as lists of gene identiﬁers
reported by diﬀerent publications without reference to numerical detail. The resulting simplicity of database design enables eﬃcient cross-experiment
and cross-platform gene annotation needed for meta-analysis. (B) Gene expression signatures are deposited in a relational MySQL database with
three logical areas of database schema: tables are related to genes, lists and publications. (C) Signatures classiﬁed by the type of identiﬁer used in the
original publication. (D) Number of publications studying model systems, patient samples or both. (E) Number of publications classiﬁed by origin of
tumors studied.
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scription factor binding motifs in promoter sequences
which are referred to as cis-regulatory modules. The
number of signatures a module is required to be part of is
called support (Figure 3A). Signiﬁcance of co-occurrence
is evaluated using a generalized form of the Binomial
Distribution with trial-speciﬁc probabilities (see ‘Materials
and Methods’ section for details). Thus, there are three
parameters that inﬂuence the number of signiﬁcant
co-occurrence modules: module size, support and
Z-score. Each signiﬁcant co-occurrence module is repre-
sented as a fully connected undirected graph where genes
are nodes and edges are drawn between all pair-wise
combinations of genes (Figure 3B). For a set of signiﬁcant
co-occurrence modules, this procedure leads to a network
whose numbers of nodes and edges are determined by the
stringency of the analysis. Performing the analysis on
randomized signatures allows evaluating the eﬀectiveness
of a given set of parameters.
The impact of varying the three analysis parameters is
illustrated in Figure 3C–E. Signal-to-noise ratios (SNR)
are calculated by dividing the number of nodes/edges/
modules in the real network by the corresponding number
of nodes/edges/modules in the randomized network.
Figure 3C shows the eﬀect of raising the Z-score cutoﬀ
on the SNR for module size 3 and support 5. Figure 3D
Figure 2. Nonuniform distribution of gene occurrences. (A) Graph showing absolute and relative occurrence frequency of PubLiME genes. Relative
occurrence frequency is calculated by dividing the absolute occurrence number by the number of studies where the gene was represented on the
microarray platform employed. (B) Five hundred most frequently occurring genes are expressed at higher levels and in more tissues (last column) as
compared to genomic average. Expression is measured in transcripts per million as reported in Unigene Hs.198 expression proﬁles. Log-transformed
Wilcoxon signed rank sum test P-values are shown. (C) Most occurring genes have longer CpG islands overlapping annotated transcription start sites
and more annotated alternative transcripts with diﬀerent 50-ends. Upper panel: Q–Q plot of genome-wide distribution of CpG island lengths which
are overlapping annotated transcription start sites. The plot shows that CpG island lengths follow a nearly normal distribution with some
overrepresentation of shorter CpG islands. Middle panel: comparison of genome-wide distribution of CpG island lengths (‘all’) with the distribution
of CpG island lengths that are overlapping with start sites of 500 most occurring PubLiME genes. Pt: T-test P-value, Pw: Wilcoxon signed rank test
P-value (performed because CpG island lengths distribution is not perfectly normal). Lower panel: the distribution of relative occurrence frequencies
was calculated for PubLiME genes having exactly one annotated 50-end or more than the indicated number of diﬀerent alternative 50-ends. P-value is
calculated using Wilcoxon signed rank sum test.
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size 3 and Z-score cutoﬀ 7. Support 5 was found to give
the best SNR and was used for all further analyses. In
other words, we required a module to be observed in at
least ﬁve publications. This requirement eliminates the
need to include genes in the analysis which are present in
less than ﬁve signatures. Thus, 1642 out of 7476 human
genes annotated in PubLiME are included in the analysis.
Figure 3E depicts the number of modules in the real and
randomized networks as a function of module size for
support 5 and Z-score cutoﬀ 7. Most modules are being
identiﬁed with module sizes 5 and 6 while the best SNR
(41000) is obtained with module sizes 7 and 8. While at
module size 3a SNR of 38 is obtained, the SNR at module
size 2 was found less than ﬁve for varying Z-score cutoﬀs,
indicating that co-occurrence analysis at module size 2 is
not very informative. We conclude that highly signiﬁcant
co-occurrence modules can be identiﬁed in PubLiME.
Please note that modules are deﬁned from purely
qualitative data.
Community formation ofgenes in
co-occurrence module graph
To address the question whether the co-occurrence
modules are forming distinct gene sets, we sought to
identify strongly connected communities in co-occurrence
module graphs. Figure 4A shows the graph representation
of co-occurrence modules with module size 3, support 5
and Z-score cutoﬀ 5. Community identiﬁcation in this
graph was carried out following an approach proposed by
Newman (10), which is based on recursively removing
edges with the largest edge-betweenness. In short, edge-
betweenness is a measure that identiﬁes edges in ‘between’
highly connected communities. Recursive removal of
edges leads to a partitioning of the graph into separate
communities. The fraction of edges connecting nodes
within communities as opposed to edges connecting
nodes between communities can be used to deﬁne graph
modularity which assumes values above 0.3, rarely
exceeding 0.7, upon removal of relatively few edges in
modular graphs (10) (see ‘Materials and Methods’ section
for details).
We applied this algorithm to co-occurrence module
graphs for module sizes 10 to 3 (see supplementary ﬁle
‘community_composition.xls’). Figure 4B shows the
development of graph modularity upon removing edges
from the graph shown in Figure 4A and its randomized
counterpart. Graph modularity reaches a value of 0.52
upon removal of 231 edges indicating the presence of
communities in this graph while in the randomized graph
the modularity is mainly negative. We noticed that
removing the number of edges corresponding to maximal
graph modularity often leads to a partitioning of the
graph into communities with highly related functions
(as measured by Gene-Ontology-term enrichments).
Therefore, we adopted a diﬀerent strategy for community
deﬁnition. Starting from high module sizes, we ﬁrst
identiﬁed the most signiﬁcant community forming genes.
With decreasing module size, more genes will be inserted
into the diﬀerent communities. The number of edges to be
removed from the graph at a given module size was
required to minimize the separation of genes that had
been assigned to a community at higher module sizes.
A detailed report of community composition at diﬀerent
module sizes is shown in the supplementary ﬁle ‘commu-
nity_composition.xls’. Genes with changing community
assignment at diﬀerent module sizes were excluded from
the analysis (10 in total). Figure 4C depicts the commu-
nities that are identiﬁed upon removal of 91 edges
from the graph of module size 3, support 5 and Z-score
cutoﬀ 5, designated C1 to C7. Communities composed of
four or fewer genes were not considered further. Gene-
Ontology-term enrichment analysis was used to deﬁne the
putative biological role of these communities: C1—cell
cycle (P¼3.8 E-23), C2—phosphorylation (P¼2.9 E-11),
C3—interferon induction (P¼1.8 E-11), C4—extracellu-
lar matrix (P¼6.6 E-13), C5—immune response (P¼2.6
E-4), C6—unknown, C7—cell cycle (P¼3.6 E-5) and
apoptosis (P¼7.6 E-5).
A similar deﬁnition of communities was obtained by
using CFinder, a software that identiﬁes partially over-
lapping communities by searching k-cliques sharing at least
one edge (11) (supplementary ﬁle ‘community_composi-
tion.xls’). Only communities containing more than four
genes were considered. In general, CFinder assigns fewer
genes to communities and tends to break–up related gene
sets as shown by Gene-Ontology-term enrichment.
However, assignment of single genes to diﬀerent commu-
nities is surprisingly rare and limited to the two largest
communities, suggesting that the communities do reﬂect
distinct rather than strongly overlapping biological func-
tions. Interestingly, the gene assigned to most communities
is MYC (four communities). We conclude that genes
making up published gene expression signatures can be
partitioned into separate communities using two diﬀerent
approaches of community identiﬁcation.
Table 1. Genes that are occurring most frequently in PubLiME
Symbol Occurrences Detectable rel_occ_freq
CCND1 30 193 0.155
MYC 27 196 0.138
IL8 25 198 0.126
VEGF 25 198 0.126
TNFAIP3 25 198 0.126
FN1 25 198 0.126
CLU 24 199 0.121
FOS 24 199 0.121
IGFBP4 23 200 0.115
CDKN1A 23 200 0.115
TGFBI 22 201 0.109
TOP2A 22 201 0.109
JUNB 21 202 0.104
PCNA 21 202 0.104
SPARC 21 202 0.104
STAT1 21 202 0.104
SERPINE1 20 203 0.099
IGFBP3 20 203 0.099
GADD45A 20 203 0.099
LGALS1 20 203 0.099
Note: Relative occurrence frequency (rel_occ_freq) is calculated by
dividing column 2 (absolute occurrences) by column 3 (number of times
the gene was present on the array).
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Since signiﬁcant co-occurrence of genes is suggestive
of co-regulation, we sought to identify enriched cis-
regulatory modules of transcription factor binding
motifs in the promoters of genes forming diﬀerent
communities. Identiﬁcation of signiﬁcant cis-regulatory
modules was carried out following the same procedure
used for detection of co-occurrence modules of genes in
diﬀerent signatures, i.e. co-occurrence of combinations of
binding motifs in promoters of community genes is tested.
The resulting graph of cis-regulatory modules is not tested
for the presence of communities, however, but visualized
with the aim of identifying the most common motif which
will be characterized by the highest node degree (# of
edges). In addition, the PageRank algorithm (JUNG
software) is used that identiﬁes the node visited most
frequently upon random walks along the graph (Figure 5,
node size represents PageRank).
For the cell cycle community, E2F was identiﬁed as the
motif having the largest node degree and page rank. The
genes making up this community are strongly enriched
(P¼2.71 e-17) for genes which we have previously shown
to be under control of E2F transcription factors (RFC4,
CDC25A, RFC3, MAC30, RRM1, RRM2, BARD1,
MCM7, CCNE1, CHAF1A, EZH2, MCM4, PCNA,
TFDP1, HMGB2 and FEN1) (16,17). Motif searches in
the promoter regions of these genes indicated E2F, Sp1,
GC-boxes and NF-Y (CCAAT boxes) as strongly
enriched transcription factor binding motifs (17). In
general, a number of motifs were identiﬁed whose role in
the regulation of genes making up the respective commu-
nities is either known or compatible with biological
Figure 3. Co-occurrence analysis of genes in PubLiME signatures. (A) Parameters of co-occurrence analysis. A module is a set of genes. Module size
indicates the number of genes required to co-occur in diﬀerent signatures. Support is the number of signatures a module is required to be part of.
PMID is the PubMed identiﬁer. (B) Graph representation of a module. Genes are represented as nodes. Edges are drawn between all pair-wise
combinations of genes creating a fully connected graph. Numbers under each graph indicate module size. (C) Signal-to-noise ratio (SNR) as a
function of Z-score cutoﬀ. SNR is calculated as the number of nodes (upper panel) or edges (lower panel) in the network resulting from the
combination of graph representations of all signiﬁcant modules divided by the corresponding number of nodes (edges) in a network resulting from
the analysis of randomized signatures. Module size¼3, support¼5. (D) SNR as a function of support. Module size¼3, Z-score cutoﬀ¼7.
(E) Number of nodes and edges as a function of module size in networks resulting from the analysis of real and randomized signatures. Support¼5,
Z-score cutoﬀ¼7.
2350 Nucleic Acids Research, 2007, Vol. 35, No. 7intuition. For example, promoters in the extracellular
matrix community are found enriched for SOX5 and
SOX9 (Figure 5) which were reported to cooperatively
activate expression of the COL1A1 promoter (18).
Promoters of the immune response community are rich
in NFKB and OCT factor binding motifs, known
regulators of inﬂammation (19) and tissue-speciﬁc expres-
sion of immune system genes (20). In the interferon
community we ﬁnd strong enrichment of interferon
regulatory factors 1 and 7 (IRF1, IRF7), known
mediators of the interferon response (21,22).
Publications reporting signatures enriched
in pathwaytargets
We queried PubLiME for the identiﬁcation of publica-
tions reporting gene lists that are signiﬁcantly overlapping
with pathways targets. The results of these queries are
documented in the supplementary ﬁle ‘conditions_over-
laps.xls’. The pathway targets have been identiﬁed in
publications reporting human expression proﬁles. Thus,
for human expression proﬁles, this approach is somewhat
circular. It nevertheless provides a detailed account of
conditions that lead to deregulation of pathway targets.
For murine expression proﬁles, instead, signiﬁcant and
meaningful overlap with pathway targets can be taken
as an independent proof that the pathways identiﬁed
are biologically relevant and to illustrate that cross-
platform and cross-organism annotation are working
correctly.
We identiﬁed six publications reporting signiﬁcant
overlap with cell cycle targets (C1), two publications
with enrichment of immune response targets (C5), one
publication with enrichment for interferon response genes
(C3), two publications enriched for ECM targets (C4) and
one publication with enrichment for cell cycle/apoptosis
Figure 4. Identiﬁcation of communities in the graph formed by signiﬁcant co-occurrence modules. (A) Visualization of co-occurrence module graph
with module size 3, support¼5, Z-score cutoﬀ¼5. Some highly interconnected parts of the graph are connected to the body of the graph by very
few edges which will be removed from the graph early in the process of edge-betweenness clustering leading to the formation of separate communities
and to a corresponding steep increase in graph modularity. (B) Graph modularity as a function of the number of edges removed from the graph in
the real and randomized co-occurrence module graph of module size¼3, support¼5, Z-score cutoﬀ¼5. The maximum of graph modularity
determines the number of edges to be removed from the graph for the deﬁnition of communities. (C) Communities deﬁned by removal of 91 edges
from the co-occurrence module graph of module size¼3, support¼5, Z-score cutoﬀ¼5.
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niﬁcant overlap with cell cycle targets are studying MEFs
with knockout of pocket protein family members pRB,
p107 and p130 (23), MEFs stimulated with serum and
comparison of growth-regulated genes with E2F target
genes (24) and expression of SV40 Large T Antigen in
neuroendocrine cells (25). The studies with overlapping
immune response targets are reporting expression changes
in dendritic cells pulsed with tumor antigens (26), and
IL-12 treatment of mammary carcinoma cells in vivo (27).
Deregulation of ECM target genes was reported in mouse
cell line models with diﬀerential tumorigenicity and
metastatic potential (28,29). The human signatures being
enriched for pathway target genes show that there is a
slight prevalence for blood cell neoplasm studies showing
overlap with phosphorylation cascade genes (C2), that the
interferon pathway targets (C3) are overlapping with
studies employing interferon treatment of cells, and that
studies with overlap to ECM genes (C4) are concerned
with tumor progression and metastasis. Even though
human signatures enriched in pathway targets cannot
provide an independent proof, taken together with the
overlapping murine signatures, it appears that the cancer
signaling pathways identiﬁed in this study do reﬂect
biologically relevant phenomena and that the approach
presented here, in conjunction with more extended
Figure 5. Cis-regulatory modules enriched in promoters of community forming genes. Co-occurrence of two up to ten transcription factor motifs in
promoters of community forming genes were identiﬁed in real promoters and in promoters with randomized assignment of transcription factor
binding motifs. A signal-to-noise ratio is calculated by dividing the number of co-occurrence modules in real promoters by the corresponding number
in randomized promoters as a function of module size. Cis-regulatory modules obtained at module sizes giving the best signal-to-noise ratio are
visualized using Netsight software. Node size indicates PageRank, a measure indicating how often a node is visited in random walks along the edges
of the graph. Transcription factor binding motifs that are part of many cis-regulatory modules will have both a high node degree as well as a high
PageRank. All modules were required to be present in at least one-third of the promoters analyzed.
2352 Nucleic Acids Research, 2007, Vol. 35, No. 7datasets, can help identifying critical regulators of the
oncogenic process.
DISCUSSION
Here we present and illustrate the utility of a repository
of cancer-related gene expression signatures, PubLiME.
As opposed to other repositories of microarray data such
as ArrayExpress, GEO, CIBEX and Oncomine, PubLiME
stores gene identiﬁers of genes found diﬀerentially
regulated in microarray experiments but no numerical
data. This approach facilitates cross-platform annotation
of gene expression signatures needed for eﬃcient meta-
analysis by enormously simplifying database design.
The meta-analysis of PubLiME content presented here
is based on using purely qualitative data. No reference is
made to any numeric detail and no distinction is made
between up and down-regulation of genes. There are three
main reasons for proceeding this way: First, the concept of
up or down-regulation requires the deﬁnition of a base line
condition relative to which changes are measured. This is
feasible when few conditions are analyzed. During meta-
analysis of hundreds of conditions, there will be many
base-line conditions deﬁned by diﬀerent studies. Since
current gene expression technology does not provide copy
numbers of RNAs, the relative expression levels of genes
in diﬀerent base-line conditions cannot be obtained.
Therefore, we just consider whether a gene displays
changing expression levels in a given set of conditions.
Secondly, the interpretation of the direction of change can
be very misleading in the absence of a detailed numerical
model of the underlying gene network, which is currently
unavailable. For example, we observed counter-intuitive
up-regulation of BCL2 by E2F1 even though E2F1
induces apoptosis (16). Thirdly, genes are often repre-
sented in a many-to-many relationship on diﬀerent array
platforms. During meta-analysis, it is necessary to deﬁne
summary measures, which is nontrivial because one has to
reconcile often contradictory readouts of diﬀerent probes
measuring the same gene. If one gene is measured by
two probes in, say, 200 diﬀerent conditions, there are
2
200¼1.60694Eþ60 diﬀerent readouts to be reconciled
for a single gene!
Considering these potential complications, we explored
the possibility of detecting biologically meaningful asso-
ciations of genes from co-occurrence patterns of gene
combinations in diﬀerent gene expression signatures. The
hypothesis tested here is that downstream target genes of
cancer signaling pathways should signiﬁcantly co-occur in
gene expression signatures identiﬁed in diverse conditions
impacting the activity of cancer signaling pathways. We
have adopted a combination of co-occurrence analysis of
genes in diﬀerent signatures with a graph-based approach
aimed at identifying strongly interconnected communities
of co-occurring genes. We found that such communities
do exist and that the genes constituting those communities
share considerable similarities in biological function as
determined by analyzing gene annotations, cis-regulatory
modules enriched in their promoter regions, and over-
lapping signatures in independent mouse experiments.
The analysis of occurrence frequencies of genes in
PubLiME signatures revealed a highly nonuniform
distribution which cannot be attributed to diﬀerent
numbers of times a gene was present on a microarray
platform. Among the most frequently occurring genes we
found many oncogenes raising concerns that the
PubLiME signatures are biased because researchers may
tend to focus on known cancer genes. However, PubLiME
signatures represent the outcome of statistical analyses of
microarray studies listing signatures of median length 52.
Researcher bias would require the favorite gene to be
explicitly added to those signatures if it was not already
present. Second, among the most frequently occurring
genes there are many which are not among the most
widely studied cancer genes such as Clusterin (24
signatures), TNFAIP3 (25 signatures), CD24 (20 signa-
tures) or genes with unknown function such as C5orf13
(12 signatures). Third, the most frequently occurring genes
are characterized by higher expression levels, expression
in a larger number of tissues, and larger CpG islands
covering their annotated transcription start site. CpG
islands are associated with alternative start sites of
transcription (15). Indeed, genes with more annotated
alternative transcripts have a higher occurrence rate in
PubLiME signatures. It is tempting to speculate that the
occurrence rate of genes in signatures is partly determined
by the number of alternative promoters that respond to
diﬀerent aﬀerent signals. In any case, these evidences
make it seem unlikely that the nonuniform distribution of
occurrence probabilities is due to researcher bias for
favorite cancer genes.
Microarray studies are inherently error prone due
to uncertainties in probe speciﬁcities and sensitivities,
varying methods of analysis and sample impurities. Gene
annotation is another potential source of error. Thus,
robustness of meta-analysis with respect to noise is a valid
concern. We found our approach to be robust because
even in the presence of 20% of mis-assigned genes per
signature, the modularity of the graph and the
communities identiﬁed hardly changed (Supplementary
Figure S4). We believe that the robustness is a result of
module sizes bigger than two applied in this analysis. Since
an edge is drawn between two genes when they are part of
the same signiﬁcant co-occurrence module, for module
size two there is only one module (the one composed of
the two genes under analysis) that determines the presence
or absence of an edge. For module sizes larger than two,
every pair of genes is part of many modules and only one
of them needs to be signiﬁcant for an edge to be drawn.
Thus, even though moderate levels of noise will impact the
signiﬁcance of a considerable number of modules, only
extreme levels of noise will eliminate all of them. Noise
resistance is also illustrated by the fact that communities
identiﬁed at highly stringent large module sizes (4–10)
contained fewer genes (as expected) but the genes that
were part of the same community at large module size did
hardly ever change community at module size three
(see supplementary ﬁle ‘community_composition.xls’).
The second reason for noise tolerance is the relatively
large number of signatures stored in PubLiME (233
human, 40 mouse). For a co-occurrence module to be
Nucleic Acids Research, 2007, Vol. 35, No. 7 2353considered in further analysis, it is required to occur
signiﬁcantly in at least ﬁve diﬀerent signatures. Thus, the
modules analyzed for community formation have been
validated by independent studies.
The identiﬁcation of signiﬁcant co-occurrence modules
applied here is based on the abstraction of distinct list-
entry pairs where a list is represented by gene expression
signatures composed of genes as entries, or by promoters
listing transcription factor motifs. The co-occurrence
probability of combinations of entries (modules) is
calculated using a generalized form of the Binomial
Distribution with trial-speciﬁc probabilities. This distribu-
tion is needed because of list length heterogeneity which
causes the occurrence probabilities of entries to be list-
speciﬁc. It is based on the Binomial Distribution because
for every list analyzed there is a binary outcome (module
present or not present). Therefore, the analysis can be
thought of as a binomial trial where at each throw of a
die a diﬀerent but distorted die is used. We have shown
that this approach is proﬁcient in identifying signiﬁcant
co-occurrence modules of genes in signatures and of cis-
regulatory modules in promoters. However, the abstract
nature of list-entry pairs renders it applicable to a wider
range of applications. For example, it would be interesting
to analyze gene expression signatures in conjunction with
ChIP on chip data for oncogenic transcription factors,
which could be accomplished by transforming ChIP on
chip data to a list-entry format where all the gene
promoters bound by a transcription factor are listed
using the same gene identiﬁers as those used in gene
expression signatures.
Although the communities identiﬁed here are charac-
terized by considerable stability, the analysis could be
improved signiﬁcantly by the availability of more gene
expression signatures in PubLiME. Therefore, we encour-
age microarray researchers to submit their signatures for
deposition in PubLiME. As mentioned previously, ChIP
on chip data would be equally welcome and suitable to
improve the deﬁnition of cancer signaling pathways and
their downstream targets. The possibility of assembling
cancer signaling pathways on-the-ﬂy, without the need for
preconﬁgured gene lists, could enable a novel, interactive
way of microarray data analysis where a researcher can
build pathways using his signature in conjunction with all
other signatures in the repository, discover how his
signatures impact pathway communities and which com-
munity the genes regulated in his signature belong to.
In conclusion, we show that genes occur in a strongly
nonrandom fashion in published gene expression signa-
tures. Co-occurrence analysis can be used to identify
co-occurrence modules of genes that are strongly over-
represented. A graph-based approach aimed at the
identiﬁcation of interconnected communities can be
applied to co-occurrence modules of genes to show that
they are forming distinct communities. The genes making
up separate communities are enriched for regulators of cell
cycle, apoptosis, phosphorylation cascades, extracellular
matrix, immune and interferon response regulators and
some of them are forming communities of unknown
function. For the majority of communities, promoter
searches for enriched cis-regulatory modules support the
conclusion that the communities identiﬁed here reﬂect
biologically relevant sets of co-regulated genes whose
expression is altered in human cancer. As such, the
identiﬁed communities may provide marker genes useful
for clinical applications as well as hitherto unknown
regulators of cancer signaling pathways that may
constitute novel entry points for pharmacological
intervention.
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